Articles from Mirai Bio

Mirai Bio, the innovation delivery partner for companies developing next generation nucleic acid medicines, today announced new preclinical data from an oral presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting 2026 demonstrating that its in vivo data-driven machine learning platform can optimize lipid nanoparticles (LNPs) for delivery to adipocytes, a historically difficult-to-reach cell type central to obesity and related metabolic diseases. The findings reinforce that delivery is a core area of therapeutic innovation, expanding the tissues nucleic acid medicines can reach and what disease biology they can address beyond the liver.

Mirai Bio, the innovation delivery partner for companies developing next generation nucleic acid medicines, today announced new preclinical data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting 2026 demonstrating the rapid advancement of its CD8-targeted lipid nanoparticle (LNP) platform from novel particle design to functional non-human primate (NHP) proof-of-concept in only 10 months. T cells are a high-value delivery frontier because of their central role in immune biology and relevance across autoimmune diseases, oncology, and other immune-mediated conditions. The two poster presentations show how Mirai’s integrated platform addresses the core requirements for in vivo T-cell targeting, including T-cell specificity, reduced liver-directed delivery, scalable production, tolerability, and functional activity in relevant models, creating a cargo-ready foundation for partner programs.

Mirai Bio, the innovation delivery partner for companies developing next generation nucleic acid medicines, today announced that it will present three abstracts at ASGCT 2026, including one oral presentation and two posters highlighting progress in two different targeted lipid nanoparticle delivery programs. Together, the presentations highlight both the rising bar for nucleic acid medicine delivery beyond the liver and how Mirai’s extensive proprietary, in vivo biodistribution data-powered machine learning approach enables best-in-class LNP design, improves selectivity and tolerability, and ensures functional performance in vivo across programs.